Azitra, Inc.

AZTR: 8-K · reverse split

Azitra, Inc. (AZTR) filed a certificate of amendment on October 22, 2026 to effect a 1-for-10 reverse stock split of its common stock, with the split becoming effective October 26, 2026 at 12:01 a.m. ET and split-adjusted trading beginning at market open that day. Every 10 issued and outstanding shares will combine into one share, with no fractional shares issued — holders receive cash in lieu based on the average closing price over the five trading days preceding effectiveness. Shareholder approval at the June 15, 2026 annual meeting authorized splits between 1-for-2 and 1-for-30 at the Board's discretion. A 1-for-10 ratio at the high end of the authorized range typically signals an effort to cure low bid-price listing compliance on NYSE American and is generally viewed negatively by retail holders, though it does not change the company's underlying economics or par value.

SEC 8-K•5d ago

Azitra, Inc. Announces Reverse Stock Split

Azitra will effect a 1-for-10 reverse stock split effective October 26, 2026, reducing issued shares from 60,603,742 to approximately 6,060,374. The board approved the final ratio on October 14 under stockholder authority granted at the June 15, 2026 annual meeting, which allowed ratios of 1-for-2 up to 1-for-30. Fractional shares will be cashed out, and equity awards and warrants will be proportionally adjusted. The filing language flags the ability or inability to maintain NYSE American listing as a risk, suggesting the split is aimed at shoring up share price for compliance.

•11d ago

AZTR: 8-K · material agreement

Azitra entered into an at-the-market sales agreement on September 28, 2026 with A.G.P./Alliance Global Partners to sell up to $3,503,232 of common stock on NYSE American. A.G.P. will earn a 3.0% cash fee on gross proceeds, and sales occur only at Azitra's discretion under its effective Form S-3 shelf, so no shares are issued immediately. Net proceeds are earmarked for working capital and general corporate purposes, providing a small funding backstop while creating incremental dilution risk for AZTR holders if utilized.

SEC 8-K•29d ago

AZTR: 424B5 · prospectus supplement

Azitra filed a 424B5 prospectus supplement establishing a $3.5 million at-the-market offering through A.G.P./Alliance Global Partners, paying a 3.0% commission on gross proceeds. The ATM capacity equals roughly one-third of Azitra's ~$10.5 million public float — the cap under Form S-3 General Instruction I.B.6 — meaning the raise is already at the maximum permitted size and further raises will need alternative vehicles. The filing highlights financial strain: the company paused its ATR-12 Phase 1b trial in Netherton syndrome for capital preservation, holds $5.9 million in working capital, and states proceeds plus cash will not fund operations for the next 12 months. AZTR trades near $0.17, recently regained NYSE American listing compliance, and faces a new $0.25 minimum trading price rule effective July 1, 2027 — dilution and delisting risk remain elevated.

SEC 424B5•29d ago

AZTR: 10-Q · periodic report

Azitra's 10-Q for the six months ended June 30, 2026 carries explicit going-concern language: with a $75.8 million accumulated deficit, a $7.3 million six-month net loss, and no product revenue, management states there is substantial doubt about the Company's ability to continue as a going concern for the next twelve months. Cash stood at $6.7 million after a $10.4 million Series A PIPE in March 2026, in which the CEO, a consultant, and a >5% holder participated.

SEC 10-Q•2mo ago

AZTR: 8-K · amendment

Azitra stockholders approved a Certificate of Amendment increasing the total number of authorized common shares from 200 million to 750 million shares. This significant expansion of authorized capital was filed with the Delaware Secretary of State on June 15, 2026. In a move typically associated with maintaining compliance with listing standards, shareholders also authorized the Board of Directors to effect one or more reverse stock splits. Proposal 3 passed with 645,704 votes for and 550,065 votes against. Additional approvals included the ratification of Grassi & Co. as the independent registered public accounting firm and authorization to issue more than 19.99% of outstanding stock to financing partner Alumni Capital LP.

SEC 8-K•4mo ago

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra adjourned its 2026 Annual Meeting originally held on June 4 to June 15, 2026, because it failed to achieve a quorum. Only approximately 17% of outstanding shares were represented by proxy at the meeting, falling short of the required 33 1/3% threshold. Management is requesting stockholders as of the April 24 record date to submit their proxies before the new 10:59 a.m. ET deadline on June 15.

•4mo ago

AZTR: S-1 · offering registration

Azitra, Inc. (AZTR) filed an S-1 registration statement to allow selling stockholders to resell up to 255.7 million shares of common stock, which represents approximately 1,580% of the 16.2 million shares currently outstanding. This massive dilution stems from a private placement closed in March 2026, where the company issued Series A Preferred Stock and Series B/C Warrants to investors for $10.5 million in initial proceeds. The filing reveals severe financial distress, with auditors issuing a going-concern opinion due to accumulated deficits and negative cash flow. The company reported only $5.0 million in total assets and $2.0 million in working capital as of December 31, 2025, stating that current cash is sufficient for only nine months of operations. Additionally, Azitra faces imminent delisting risk from NYSE American for failing to meet continued listing requirements, with a compliance deadline of April 1, 2027. The stock traded at $0.19 per share in mid-May 2026, down from an IPO price of $999.00 in 2023, highlighting the extreme volatility and loss of value for early investors.

SEC S-1•5mo ago

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

prnewswire.com•8mo ago